These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32571749)

  • 21. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.
    Zhu S; Zhang H; Dong Y; Wang L; Xu Z; Liu W; Gan Y; Tang H; Chen D; Wang F; Zhao P
    J Hepatol; 2018 Jun; 68(6):1123-1128. PubMed ID: 29452204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
    Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study.
    Lu H; Geng da Y; Shen F; Zhang JY; Lu B; Ma LX
    Virol J; 2011 Sep; 8():444. PubMed ID: 21936898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.
    Wang CC; Tseng KC; Peng CY; Hsieh TY; Lin CL; Su TH; Tseng TC; Hsu CS; Lin HH; Kao JH
    J Gastroenterol Hepatol; 2013 Jan; 28(1):46-50. PubMed ID: 22989322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.
    Brahmania M; Lombardero M; Hansen BE; Terrault NA; Lok AS; Perrillo RP; Belle SH; Di Bisceglie AM; Feld JJ; Lee WM; Fried MW; Janssen HLA;
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2541-2551.e2. PubMed ID: 30743006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Establish a predictive modeling under antiviral therapy for hepatitis B e antigen seroconversion in chronic hepatitis B].
    Liu GW; Tang KC; Li Q; Lu W
    Zhonghua Gan Zang Bing Za Zhi; 2018 Sep; 26(9):641-645. PubMed ID: 30481858
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B.
    Wu Y; Wen J; Tang G; Zhang J; Xin J
    J Infect; 2021 Nov; 83(5):594-600. PubMed ID: 34474058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone.
    Ren S; Wang W; Lu J; Wang K; Ma L; Zheng Y; Zheng S; Chen X
    Front Immunol; 2022; 13():1035923. PubMed ID: 36389814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
    Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA.
    Yao K; Wang J; Wang L; Xia J; Yan X; Wu W; Liu J; Wang L; Yin S; Tong X; Ding W; Huang R; Wu C
    J Med Virol; 2022 Feb; 94(2):659-666. PubMed ID: 34499353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Differential liver histopathological features of chronic HBV infection patients with normal and mildly elevated serum ALT].
    Ying RS; Yang Z; Chen YY; Yang KL; Xiao YH; Wu LJ; Fan HM
    Zhonghua Gan Zang Bing Za Zhi; 2012 Aug; 20(8):585-8. PubMed ID: 23207151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa.
    Shimakawa Y; Njie R; Ndow G; Vray M; Mbaye PS; Bonnard P; Sombié R; Nana J; Leroy V; Bottero J; Ingiliz P; Post G; Sanneh B; Baldeh I; Suso P; Ceesay A; Jeng A; Njai HF; Nayagam S; D'Alessandro U; Chemin I; Mendy M; Thursz M; Lemoine M
    J Hepatol; 2018 Oct; 69(4):776-784. PubMed ID: 30104154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.